Healthcare Industry News: diabetic nephropathy
News Release - January 4, 2006
Keryx Biopharmaceuticals, Inc. Announces Appointment of Senior Pharmaceutical Executive to Board of DirectorsJonathan Spicehandler, M.D., Chairman of Schering Plough Research Institute, Joins Board
NEW YORK, Jan. 4 (HSMN NewsFeed) --Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced the appointment of Jonathan Spicehandler, M.D., to the Company's Board of Directors.
Dr. Spicehandler played a major leadership role in the development and approval of several well-known drugs, including: (1) intron-A® (recombinant interferon-alpha 2-b), for the treatment of malignant melanoma, hairy cell leukemia, AIDS-related Kaposi's sarcoma, chronic hepatitis C and chronic hepatitis B, (2) temodar® (temozolomide) for the treatment of glioblastoma and refractory anaplastic astrocytoma, (3) Clarinex®/Claritin® (anti-histamine), for the treatment of seasonal allergic rhinitis, (4) peg-intron® (pegilated interferon-alpha 2-b), for the treatment of hepatitis C, and (5) rebetol® (ribavirin), for the treatment of hepatitis C in combination with interferon.
"We are very excited that Dr. Spicehandler has agreed to join our Board of Directors," stated Michael S. Weiss, chairman and chief executive officer of Keryx. Weiss continued, "With his extensive range of pharmaceutical experience, Dr. Spicehandler's participation on the board and his guidance will further enhance our efforts to become a leading biotechnology company."
Dr. Spicehandler also serves as a director of XTL Biotechnologies, Ltd., also a publicly-traded biotechnology company.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is KRX-101 (sulodexide), a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. KRX-101 is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
Source: Keryx Biopharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.